← All stocks

Arcutis Biotherapeutics, Inc.

ARQT Mostly scheduled
CIK 0001787306 #1713 in the set updated 22 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$17.37M
$10.64M on a plan · $5.95M straight out of an exercise
Sold at will
$778.75K
2 of 84 sales
Net
−$17.37M
−$778.75K against sales at will

By person

16 insiders · 84 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Watanabe Todd
See Remarks
$5.32M (13) scheduled
−$5.32M
742,613
0.5908%
$18.57M
−8.3%
Welgus Howard G.
Director
$2.43M (14) scheduled
−$2.43M
35,841
0.0285%
$896.06K
−81.3%
Matsuda Masaru
See Remarks
$2.21M (18) scheduled
−$2.21M
112,508
0.0895%
$2.81M
−40.8%
Burnett Patrick
See Remarks
$2.02M (18) scheduled
−$2.02M
117,592
0.0936%
$2.94M
−44.4%
Leonard Keith R
Director
$997.19K (1) scheduled
−$997.19K
27,901
0.0222%
$697.55K
+48.2%
Curran Terrie
Director
$984.04K (3) scheduled
−$984.04K
23,526
0.0187%
$588.17K
+25.0%
Edwards Larry Todd
See Remarks
$968.36K (6)
−$968.36K
175,178
0.1394%
$4.38M
+23.5%
Krishnamohan Neha
Director
$939.49K (2) scheduled
−$939.49K
27,901
0.0222%
$697.55K
+77.2%
LIN SUE-JEAN
Director
$898.54K (2) scheduled
−$898.54K
27,567
0.0219%
$689.20K
+44.1%
Gilbert Halley E
Director
$455.44K (1) scheduled
−$455.44K
27,901
0.0222%
$697.55K
+48.2%
Vairavan Latha
SVP Chief Financial Officer
$148.50K (6) scheduled
−$148.50K
85,978
0.0684%
$2.15M
+90.6%
CHAUDHURI BHASKAR
Director
867,826
0.6904%
$21.70M
+0.9%
Topper David Joseph
Chief Financial Officer
182,774
0.1454%
$4.57M
+7.5%
Heron Patrick J
Director
59,661
0.0475%
$1.49M
+216.9%
Munshi Amit
Director
9,799
0.0078%
$244.98K
+390.0%
Peetz Christopher
Director
4,315
0.0034%
$107.88K
Insider
Date
Role
Action
Shares
Price
Amount
Burnett Patrick
19 Aug 2026
See Remarks
Sell
1,697
$27.00
$45.82K
Edwards Larry Todd
6 Nov 2025
See Remarks
Sell
29,131
$25.16
$732.93K

What was left out

Form 4 filings counted 68
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 64
Sales straight out of an exercise 18
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 507,852
History held since 3 Feb 2020